Study guide
21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics
Board Certified Pediatric Pharmacy Specialist BCPPS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure
1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation
2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles
2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development
3 Chapter 3: Neonatal Critical Care & Prematurity Complications
3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis
4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections
4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections
5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections
5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections
6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus
6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices
7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders
7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities
8 Chapter 8: Pediatric Cardiology & Hemodynamics
8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management
9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support
9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK
10 Chapter 10: Pediatric Neurology & Psychiatric Disorders
10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders
11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders
11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia
12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care
12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care
13 Chapter 13: Pediatric Medication Safety & Error Prevention
13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions
14 Chapter 14: Pediatric Compounding & Formulation Technology
14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities
15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support
15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation
16 Chapter 16: Pediatric Pain Management, Sedation & Delirium
16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies
17 Chapter 17: Biostatistics & Study Design in Pediatric Research
17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values
18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics
18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations
19 Chapter 19: Pediatric Education, Health Literacy & Communication
19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials
20 Chapter 20: Pediatric Immunizations & Public Health Advocacy
20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy
21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics
21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management
21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics
Key Takeaways Explain This Topic AI
The four pharmacoeconomic analyses are distinguished by how outcomes are measured: cost-minimization assumes proven equivalent outcomes and compares cost only, cost-effectiveness reports cost per natural unit such as cost per exacerbation avoided, cost-utility reports cost per quality-adjusted life year, and cost-benefit converts outcomes to currency.
The incremental cost-effectiveness ratio is the difference in cost between two strategies divided by the difference in effect; a lower ICER is more favorable, and US willingness-to-pay thresholds are commonly cited between $50,000 and $150,000 per quality-adjusted life year.
Pediatric economic evaluations must use a societal or at least caregiver-inclusive perspective, because caregiver lost productivity and travel often exceed direct medical costs, and must use pediatric-validated utility instruments such as EQ-5D-Y, HUI2, or HUI3 rather than adult instruments.
Because children accrue decades of quality-adjusted life years from a successful intervention while adult discounting at the conventional 3% annual rate heavily devalues distant benefits, the choice of discount rate can change whether a pediatric therapy appears cost-effective.
Children's hospitals became eligible 340B covered entities under the Deficit Reduction Act of 2005 and are expressly carved out of the 340B orphan drug exclusion that applies to free-standing cancer hospitals, critical access hospitals, rural referral centers, and sole community hospitals; 340B pricing, standardized concentrations, dose rounding, and single-dose container sharing are the main levers for containing pediatric drug cost without changing therapy.
Last updated: September 2026
21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics
The BPS Pediatric Pharmacy content outline lists Pharmacoeconomics (e.g., cost-containment, formulary management) under Practice Management. On the examination this appears in two guises: a methodological question that asks you to name the right analysis type or compute an incremental cost-effectiveness ratio, and an applied question that asks how a pediatric pharmacist should present a therapeutic to a Pharmacy and Therapeutics committee.
The Four Analyses, Distinguished by How Outcomes Are Measured
Every pharmacoeconomic analysis measures costs in currency . What separates the four types is the unit in which outcomes are expressed.
Analysis Outcome unit When it is the right choice Pediatric example
Cost-minimization (CMA) None — outcomes assumed proven equivalent Only valid after equivalence has been demonstrated, not assumed Two interchangeable third-generation cephalosporins with identical spectrum and identical clinical cure rates; choose on acquisition plus preparation cost
Cost-effectiveness (CEA) A natural clinical unit Comparators share the same outcome measure Cost per vaso-occlusive crisis avoided; cost per pulmonary exacerbation averted; cost per case of respiratory syncytial virus hospitalization prevented
Cost-utility (CUA) Quality-adjusted life years (QALYs) Comparing across different diseases or when quality of life dominates Cost per QALY of a CFTR modulator versus best supportive care; the standard for formulary and payer decisions
Cost-benefit (CBA) Currency — outcomes monetized Comparing programs with entirely unlike outcomes; yields a net monetary benefit or benefit-to-cost ratio A hospital-wide pediatric antimicrobial stewardship program versus a medication reconciliation program
Important
The single most common examination error is calling an analysis a cost-minimization study when equivalence was assumed rather than demonstrated. If the trial did not establish equivalence, the correct design is a cost-effectiveness analysis.
The Incremental Cost-Effectiveness Ratio ICER = C new − C comparator E new − E comparator \text{ICER} = \frac{C_{\text{new}} - C_{\text{comparator}}}{E_{\text{new}} - E_{\text{comparator}}} ICER = E new − E comparator C new − C comparator
The ICER is the extra cost purchased per extra unit of benefit . Lower is more favorable.
Worked example. A new inhaled therapy for pediatric asthma costs $4,800 per patient-year and produces 0.62 exacerbations per year. Standard therapy costs $1,200 per patient-year and produces 0.94 exacerbations per year. ICER = 4,800 − 1,200 0.94 − 0.62 = 3,600 0.32 = $ 11,250 per exacerbation avoided \text{ICER} = \frac{4{,}800 - 1{,}200}{0.94 - 0.62} = \frac{3{,}600}{0.32} = \$11{,}250 \ \text{per exacerbation avoided} ICER = 0.94 − 0.62 4 , 800 − 1 , 200 = 0.32 3 , 600 = $11 , 250 per exacerbation avoided
Interpretation requires a benchmark: if the average pediatric asthma admission costs $14,000, the new therapy is plausibly cost-saving from the payer perspective; if most avoided exacerbations would have been managed in clinic, it is not.
Dominance. A strategy that is both less costly and more effective is dominant and no ratio is needed. A strategy that is more costly and less effective is dominated and should be rejected outright. ICERs are only informative in the trade-off quadrants.
Willingness-to-pay. In cost-utility analysis, results are judged against a threshold. United States analyses commonly cite $50,000 to $150,000 per QALY ; the Institute for Clinical and Economic Review typically reports a $100,000 to $150,000 per QALY range. No threshold is legally binding in the United States, and none accounts well for ultra-rare pediatric disease.
What Makes Pediatric Pharmacoeconomics Different FOUR PEDIATRIC-SPECIFIC METHODOLOGIC PROBLEMS
- 1. PERSPECTIVE A payer perspective misses the parent who left work
- for 9 days. In pediatrics, caregiver productivity loss
- and travel frequently exceed direct medical cost, so a
- SOCIETAL perspective is usually required for a fair
comparison.
- 2. UTILITY Adult EQ-5D is not validated in children. Use EQ-5D-Y,
- MEASUREMENT HUI2/HUI3, or PedsQL. Young children cannot self-report,
- so PROXY (caregiver) report is used and systematically
differs from child self-report.
- 3. TIME HORIZON A cure at age 3 yields ~75 years of benefit. Trials run
- & DISCOUNTING 2 years. Modeling is unavoidable, and at the conventional
- 3% annual discount rate a QALY 60 years away is worth
- about 17% of one today - which structurally disadvantages
pediatric interventions.
- 4. EVIDENCE Small populations, few randomized pediatric trials, and
- SCARCITY heavy reliance on extrapolation from adults widen every
confidence interval in the model.
Because of item 3, well-conducted pediatric analyses report results at multiple discount rates (commonly 0%, 1.5%, and 3%) in sensitivity analysis. A therapy that is cost-effective at 0% and not at 3% should be described that way, not asserted to be either.
Sensitivity analysis is what separates a credible model from an advertisement. One-way sensitivity analysis varies a single input across its plausible range; probabilistic sensitivity analysis samples all inputs simultaneously from their distributions and reports the probability of cost-effectiveness at a given threshold.
Formulary Management and the P&T Committee
The Pharmacy and Therapeutics (P&T) committee is the governing body for formulary decisions, and the evidence-appraisal and excipient-safety steps of a pediatric formulary review are detailed in the off-label pharmacotherapy section of the evidence chapter. The economic contribution a pharmacist makes to that review is a single discipline: present total cost of care, not acquisition cost. Acquisition price is one line in a budget that also contains nursing preparation and administration time, wasted drug, monitoring laboratory draws, treatment of adverse effects, and length of stay. A product with a higher unit price that is available as a ready-to-administer syringe in a standard concentration frequently wins on total cost while also reducing error risk.
Formulary tool Definition Pediatric caution
Closed formulary Only listed agents stocked; non-formulary requires an exception Must preserve rapid access for orphan and rescue therapies
Therapeutic interchange Pre-authorized substitution of a therapeutically equivalent agent under a P&T-approved protocol Requires a documented pediatric dose conversion , not an adult one
Restriction criteria Use limited by service, indication, or duration Most common for antimicrobials, IVIG, and biologics
Prior authorization Payer-side approval requirement A major access barrier for off-label pediatric use, which is the norm rather than the exception in children
Medication use evaluation (MUE) Structured retrospective or concurrent review against criteria Closes the loop after a formulary addition
Cost-Containment Levers Specific to Pediatrics
340B Drug Pricing Program. Freestanding children's hospitals became eligible covered entities under the Deficit Reduction Act of 2005 , joining disproportionate-share hospitals and federal grantees. The program requires discounted outpatient drug pricing from participating manufacturers. Compliance obligations are strict: no duplicate discounts with Medicaid rebates, no diversion to ineligible patients, and auditable records. A frequently misremembered detail: the 340B orphan drug exclusion does not apply to children's hospitals . That exclusion reaches free-standing cancer hospitals, critical access hospitals, rural referral centers, and sole community hospitals, and children's hospitals are expressly carved out of it — so a children's hospital can access 340B pricing on orphan-designated drugs, which matters enormously in a population where much of the high-cost formulary is orphan-designated.
Drug waste is a pediatric-specific cost driver. A 40 mg dose drawn from a 500 mg single-dose vial wastes 92% of the product. Countermeasures include standardized concentrations (the ASHP Standardize 4 Safety initiative), dose rounding within a defined tolerance, batch preparation of common doses, and vial sharing under USP <797> , where a single-dose container entered only in ISO Class 5 or cleaner air may be used for up to 12 hours after initial entry provided labeled storage conditions are maintained — a container punctured in worse than ISO Class 5 air must be discarded immediately.
Dose rounding is a safety intervention as well as an economy: rounding to a syringe-measurable volume eliminates the un-measurable 0.13 mL order that invites a tenfold error.
Antimicrobial stewardship remains the highest-yield cost-containment program in a children's hospital, with intravenous-to-oral conversion, automatic duration stops, and de-escalation on culture results delivering savings that dwarf acquisition-price negotiation.
Biosimilar adoption in pediatric rheumatology, gastroenterology, and oncology supportive care produces large savings, but requires attention to device usability for a child or caregiver and to state substitution law.
Practice Pearls & BCPPS Exam Traps
Exam Trap 1: Cost-utility analysis is the subtype of cost-effectiveness analysis whose outcome unit is the QALY. If the question names QALYs, the answer is cost-utility even when the stem says "cost-effectiveness."
Exam Trap 2: A lower ICER is better . Options that describe a higher ICER as more favorable are inverted.
Exam Trap 3: A dominant strategy — cheaper and more effective — does not need an ICER at all. Computing one is a distractor.
Board Rule: When presenting any pediatric therapeutic to P&T, the availability of an age-appropriate dosage form and the excipient load carried by the alternative are decision-relevant, not footnotes. A cheaper product that must be extemporaneously compounded with a propylene glycol vehicle for a neonate is not actually cheaper.